Advertisement
Table 1 Demographic and clinical characteristics
| Male gender, n (%) | 48 (58) |
|---|---|
| Age group, n (%) | |
| 16–25 years | 2 (2) |
| 26–35 years | 7 (8) |
| 36–45 years | 7 (8) |
| 46–55 years | 17 (20) |
| 56–65 years | 23 (28) |
| 66–75 years | 21 (25) |
| 76 years or older | 6 (7) |
| Ethnicity, n (%) | |
| American Indian or Alaskan Native | 1 (1) |
| Asian | 4 (5) |
| Black or African American | 2 (2) |
| Hispanic | 4 (5) |
| White/Caucasian | 70 (84) |
| Native Hawaiian or other Pacific Islander | 1 (1) |
| Māori | 1 (1) |
| Gout disease duration, n (%) | |
| Less than 6 months | 22 (27) |
| 6 months to 1 year | 10 (12) |
| 1–5 years | 22 (27) |
| 6–10 years | 13 (16) |
| 11–15 years | 5 (6) |
| More than 15 years | 11 (13) |
| Number of gout flares in past 3 months, n (%) | |
| None | 16 (19) |
| 1–2 | 47 (57) |
| 3 or more | 20 (24) |
| Gout affecting the feet, n (%) | 77 (93) |
| Tophi affecting the feet, n (%) | 29 (35) |
| Location of gout flares in the feet, n (%) | |
| Big toe joint | 59 (73) |
| Big toe | 20 (25) |
| Lesser toes | 18 (22) |
| Midfoot | 21 (26) |
| Ankle | 26 (32) |
| Heel | 8 (10) |
| Other | 10 (12) |
| Current foot pain, n (%) | 73 (88) |
| Gout medications, n (%) | |
| Non-steroidal anti-inflammatory drugs | 27 (33) |
| Corticosteroids | 9 (11) |
| Colchicine | 24 (29) |
| Allopurinol | 34 (41) |
| Febuxostat | 5 (6) |
| No medication | 8 (10) |
